2-Amino-4-Thiazole Acetic Acid

The conversion of 2-amino-4-thiazole acetic acid (ATAA) to its syn-methoxyimino derivative, (Z)-2-(2-aminothiazol-4-yl)-2-methoxyiminoacetic acid—commonly designated as aminothiazolyoximino acid (AMA)—proceeds via successive oximation and O-methylation stages in a single production train without isolation of the intermediate oxime. In a standard campaign executed in a 5000 L glass-lined, jacketed reactor equipped with a retreat-curve impeller operating at 85–95 rpm, ATAA is dissolved in a mixed solvent system of methanol and deionized water (1:0.7 v/v) at a concentration of 1.2–1.4 kmol/m³. The oximation is initiated by feeding 40% w/w sodium nitrite aqueous solution at a rate of 0.8–1.1 L/min while maintaining the internal temperature between −2 °C and +3 °C through jacket brine circulation; deviation above 5 °C raises the anti-isomer impurity fraction above 1.8%, which propagates into downstream cephalosporin diastereomers detectable at the 0.1% threshold in the final sterile powder by HPLC per USP monograph. After a 2-hour age period, dimethyl sulfate—alternatively dimethyl carbonate in facilities seeking to eliminate genotoxic impurity risk per ICH M7—is metered at a molar ratio of 1.15:1 relative to ATAA charged, with the exotherm controlled to a maximum of 12 °C to avoid excessive hydrolysis of the methylating agent. Subsequent alkaline hydrolysis at pH 10.5–11.0 using 30% w/v NaOH, followed by neutralization with HCl to the isoelectric point at pH 3.1–3.3, precipitates the AMA. The wet cake is washed with 5 °C process water and dried under vacuum (≤−0.090 MPa) at 40–45 °C until loss on drying falls below 0.5%. This isolated AMA then undergoes activation with 2,2′-dibenzothiazyl disulfide (DM) in the presence of triphenylphosphine and triethylamine, yielding the aminothiazolyoximino active benzothiazole thioester (MAEM), which is the immediate acylating agent for the β-lactam nucleus. Compliance with ICH Q7A GMP for API starting materials is mandatory; the ATAA input must meet specifications of ≥99.0% assay by anhydrous titration, individual unspecified impurity ≤0.10%, and total impurities ≤0.5%, with residual solvents limited per USP <467> (methanol ≤3000 ppm, dimethyl sulfate ≤1 ppm). The AMA esterification process described is the core upstream workflow for all subsequent cephalosporin APIs covered in this profile.

How Does the Active Thioester Derivatization Route Affect Process Mass Intensity for Third-Generation Parenterals?

The synthesis of Ceftriaxone Sodium employs 7-aminocephalosporanic acid (7-ACA) modified at C-3′ with a triazinyl-thioether substituent, 7-amino-3-[(2,5-dihydro-6-hydroxy-2-methyl-5-oxo-1,2,4-triazin-3-yl)thiomethyl]-3-cephem-4-carboxylic acid (7-ACT), as the nucleus. The acylation step conducted in anhydrous acetonitrile (water content ≤500 ppm by Karl Fischer) at a temperature of −10 °C to −5 °C uses the MAEM active thioester derived from ATAA at a molar input ratio of 1.08–1.25 mol per mol of 7-ACT, with 1.30–1.45 mol of triethylamine serving as the proton scavenger. Process mass intensity (PMI) typical of manufacturing executed in 6000 L glass-lined reactors averages 28–35 kg total solvent per kg of Ceftriaxone Sodium sterile bulk, where the acetylation and crystallization solvent system—acetonitrile, methanol, and water—contributes 65% of the mass load. The crude Ceftriaxone acid is precipitated by adjusting pH to 2.5–2.8 with dilute HCl, collected on a Nutsche filter, and reslurried in purified water at 0–5 °C before converting to the disodium hemiheptahydrate salt by addition of 10% w/v sodium 2-ethylhexanoate in acetone at 25 ± 2 °C. Crystallization is induced by seeding with micronized Ceftriaxone Sodium (D_v90 ≤ 25 μm) and controlled cooling to −8 °C over 4 hours; the resulting suspension exhibits a cubic morphology with a volume mean diameter of 45–75 μm when the jacket ramp follows a 0.3 °C/min descent. Batch failures are routinely traced to insufficient removal of the liberated 2-mercaptobenzothiazole departing group, which, if present above 0.08%, poisons the salt formation and yields amorphous precipitates instead of the stable hemiheptahydrate crystalline form. The finished product must conform to the specifications of USP 43-NF 38, Ph. Eur. 10.5, and CP 2020 monographs: assay 96.0–102.0% (anhydrous basis), pH 6.0–8.0 (aqueous dilution), identifiable impurities NMT 0.5%, acetonitrile residual ≤410 ppm, and bacterial endotoxins ≤0.20 EU/mg. The ATAA-derived AMA active ester route remains the dominant commercial pathway due to the avoidance of mixed anhydride formation, which carries explosion risks at scale and generates a difficult-to-purge pivaloyl byproduct profile.

Manufacturing routes that replace the sodium salt with the free acid form, as employed for Cefodizime—a third-generation cephalosporin with a C-3′ mercaptothiazolyl moiety—require a different final product isolation. Here the condensation of 7-amino-3-[(2-thioxo-1,3-thiazolidin-4-yl)methyl]-3-cephem-4-carboxylic acid with the same MAEM active thioester proceeds in a biphasic water–acetone system at pH 6.5–7.0, maintained by automatic titration with 20% w/v sodium carbonate. The molar ratio of active ester to nucleus is kept at 1.02–1.08:1, lower than the Ceftriaxone process, because the Cefodizime acid precipitates directly after acylation upon adjusting to pH 3.4–3.7 without requiring a separate salt-exchange step. Drying in a conical vacuum tumble dryer at 35 °C and ≤−0.095 MPa reduces moisture to ≤1.0%. The sterility assurance level (SAL) of 10⁻⁶ is achieved through aseptic processing in a Grade A/ISO 5 environment rather than terminal sterilization, imposing strict bioburden limits of ≤10 CFU/100 mL before filtration and endotoxin control of ≤0.075 EU/mg. The corresponding European Pharmacopoeia monograph 01/2021:2206 and antibacterial susceptibility breakpoint testing per CLSI M100 document drive the quality release parameters. Elimination of the sodium ion simplifies the thermogravimetric profile, as no bound water is present; however, the narrower pH window for precipitation (±0.2 units deviating from target) increases the risk of high residual 4-thiazoleacetic acid-related substances if the downstream mother liquor washing protocol is truncated below three displacement volumes. This sensitivity directly links the purity of the ATAA starting material with the Cefodizime acid crystal habit, where globular agglomerates observed under polarized light microscopy at 100× correlate with residual ATAA-AMA oligomeric esters above 0.11%.

Ceftizoxime Sodium Acylation and Isoelectric Precipitation Parameters

Ceftizoxime, an aminothiazolyl methoxyimino cephalosporin without a C-3′ acyloxymethyl group, is built from 7-amino-3-cephem-4-carboxylic acid (7-ANCA) as the nucleus. The MAEM active thioester derived from ATAA is dissolved in methylene chloride—a solvent that requires monitoring of the methylene chloride content in the final API to remain below 600 ppm per ICH Q3C Option 1 limit for Class 2 solvents—and added to a chilled solution of 7-ANCA in a water–THF mixture at −15 °C. The stoichiometry employs a molar excess of 1.10–1.20 of the active ester, and the pH is maintained at 7.8–8.2 by continuous addition of 25% w/v aqueous ammonia, a base chosen to avoid sodium ion carryover into the final zwitterion. The adoption of methylene chloride rather than acetonitrile in this specific synthesis pathway is driven by the poor solubility of 7-ANCA in acetonitrile; however, the phase transfer between the organic and aqueous layers limits the space-time yield to approximately 12–15 g/L·h in a 3000 L reactor. After phase separation, the aqueous layer is decolorized with activated carbon (0.5% w/w of the estimated product weight) and the Ceftizoxime acid is crystallized by acidification to the isoelectric point at pH 2.8–3.0 with 10% v/v sulfuric acid. Crystal habit is controlled by the addition of acetone as an anti-solvent at a constant flow rate of 0.4 L/min while lowering the batch temperature from 20 °C to 5 °C over 3 hours. The isolated acid is subsequently suspended in methanol and converted to the sodium salt using sodium bicarbonate at a 1:0.98 molar ratio, then precipitated by drowning into acetone under high shear (Reynolds number > 10⁴ in the crystallizer). The sterile powder must meet the USP 43-NF 38 specification for Ceftizoxime Sodium, with a sum of specified impurities (ceftizoxime open-ring lactone, AMA amide derivative) limited to ≤1.0% and endotoxins ≤0.10 EU/mg. Notably, the absence of a leaving group at C-3′ renders the Ceftizoxime molecule resistant to hydrolysis by human esterases, a pharmacokinetic advantage that imposes stricter diastereomer control: the anti-isomer arising from incomplete stereoselectivity in the ATAA-derived methoxyimino function must be held below 0.3% throughout the synthesis, which requires the ATAA raw material to have an anti-isomer content not greater than 0.15% before entering the oximation step.

Veterinary cephalosporin Ceftiofur, formulated as the hydrochloride or as the crystalline free acid suspension for parenteral administration in cattle and swine, begins with the same upstream AMA active ester intermediate, demonstrating the horizontal technology transfer across human and animal health value chains. The acyl acceptor in this process is furan-2-carbonylamino-cephalosporanic acid, synthesized separately from 7-ACA and furoyl chloride. The acylation coupling in aqueous acetone at 0–5 °C uses a molar ratio of 1.05:1 (active ester to nucleus) and triethylamine (1.20 eq) as the base. The Ceftiofur hydrochloride salt is precipitated by adding concentrated HCl to an isopropanol solution of the free acid, yielding a product that must satisfy the requirements of the USP Veterinary Monograph for Ceftiofur Hydrochloride: assay 92.0–105.0% on anhydrous basis, pH of reconstituted suspension 5.0–7.0, and particle size distribution D_v90 ≤ 30 μm to ensure syringability through a 16-gauge needle. The market specification for the sterile bulk also imposes a subvisible particulate matter limit of ≤6000 particles ≥10 μm and ≤600 particles ≥25 μm per vial when reconstituted, as per USP <788>, a feature driving the crystallization process to avoid needle-like habits that fracture during drying or milling. The ATAA starting material for this veterinary route may be sourced under slightly relaxed purity thresholds (assay ≥98.5%, individual impurity ≤0.20%) compared to human parenteral grade, aligning with VICH GL18 impurity guidelines; nonetheless, any carryover of thiourea residues, a potential contaminant in thiazole chemistry, must be limited to ≤5 ppm because of its documented nephrotoxic effects in target animal species. The process wastewater stream from the AMA ester activation stage, containing triphenylphosphine oxide and benzothiazole waste, requires acid–base treatment and sequential organic carbon adsorption before discharge to meet regional environmental release standards, a cost factor that can shift site-level economics toward continuous extraction loop technologies when campaign sizes exceed 50 metric tonnes per annum of ATAA throughput.

When Stoichiometric Ratios Exceed 1.15 in Ceftazidime Pentahydrate Sterile Production

Although Ceftazidime incorporates a 2-(2-aminothiazol-4-yl)-2-(1-carboxy-1-methylethoxyimino)acetic acid side chain rather than the methoxyimino chain derived directly from ATAA, the initial platform building block remains 2-amino-4-thiazole acetic acid in a substantial fraction of commercial synthesis routes. The side chain elaboration involves protection of the amino group, oxime formation with ethyl 2-hydroxyiminoacetoacetate, hydrolysis, and selective activation—a divergent path that branches after the common ATAA front-end. For those integrated facilities operating all steps under one roof, the ATAA is first converted to the protected aminothiazole acid, then subjected to oxime formation at −5 °C to 0 °C in absolute ethanol with a 1.25:1 molar charge of the oxo-ester synthon, using sodium ethoxide as the condensation promoter. The critical stoichiometric boundary of 1.15:1 for the active ester charging exists at the final acylation of 7-ACA-derived nucleus 7-amino-3-(1-pyridiniomethyl)-3-cephem-4-carboxylate: exceeding 1.15:1 during the coupling in N,N-dimethylacetamide (DMAC) at −20 °C leads to over-acylation at the C-3′ pyridinium nitrogen, generating a bis-acylated impurity that co-crystallizes with the pentahydrate form and cannot be removed by recrystallization. The downstream production of sterile Ceftazidime Pentahydrate is conducted by adding a sterile-filtered sodium carbonate solution to the free acid at pH 5.8–6.2 and temperature 38–42 °C, followed by slow cooling to 5 °C over 6–8 hours in a Grade A/ISO 5 cleanroom. The crystalline pentahydrate exhibits an endothermic dehydration event at 48–55 °C by differential scanning calorimetry, so vacuum drying is strictly limited to ≤35 °C and ≤0.5% chamber oxygen to prevent hydrate collapse. Finished product testing against Ph. Eur. 01/2021:1404 includes a pyridine limit of ≤200 ppm by headspace GC and a polymer content (high-molecular-weight impurities) limit of ≤0.3% by size-exclusion chromatography. The ATAA source must provide a certificate of analysis demonstrating the absence of β-lactam ring-opened degradation products that could act as polymerization seeds, a quality attribute verified by a dedicated stress test at 60 °C for 14 days with monthly confirmatory testing.